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ABSTRACT 
Background: In addition to their cholesterol-lowering effects, hydroxymethyl- 
glutaryl coenzyme A reductase inhibitors ("statins") might have pleiotropic, 
nonlipid effects. Insulin resistance syndrome is known to increase the risk for 
cardiovascular disease. However, the effects of statins on insulin resistance are 
a subject of controversy. 
Objective: We aimed to investigate the effects of atorvastatin on insulin 
resistance in hyperlipidemic patients. 
Methods: This 12-week, prospective, nonrandomized, open-label study was 
conducted at the outpatient cardiology clinic, Ege University Medical School, 
Bornova-Izmir, Turkey. Hyperlipidemic patients aged >18 years with insulin re- 
sistance and no other components of the metabolic syndrome were included 
in the study. Atorvastatin 10 mg QD (after the evening meal) was administered 
by mouth (tablet) over a 12-week period. At baseline and after 12 weeks of treat- 
ment, insulin sensitivity was assessed using homeostasis model assessment 
(HOMA) index methodology. Serum lipid parameters and fasting levels of 
plasma glucose and insulin (FPG and FPI, respectively) were measured at the 
same 2 time points. The tolerability of atorvastatin was assessed using labora- 
tory analysis and physical examination, including vital sign measurements. 
Results: Fifteen white patients (9 women, 6 men; mean [SD] age, 52 [8] years) 
participated in the study. No significant changes in HOMA index were found 
(mean [SD], 3.1 [1.5] vs 3.2 [1.9]). The lipid profile was improved significant- 
ly at 12 weeks compared with baseline (mean [SD] low-density lipoprotein 
cholesterol, 173.2 [21.3] vs 110.8 [43.6] mg/dL; total cholesterol, 270.9 [21.5] vs 
201.2 [46.7] mg/dL; and triglycerides, 269.5 [46.3] vs 205.5 [49.3] mg/dL; all, 
P < 0.001). No significant change in mean (SD) plasma high-density lipoprotein 
cholesterol level (45.5 [6.6] vs 43.7 [8.1] mg/dL) was found. In addition, no sig- 
nificant changes in FPG (85.3 [12.7] vs 84.8 [10.4] mg/dL), or FPI (13.5 [9.7] vs 
13.9 [10.1] pU/mL) were found. None of the patients required withdrawal of 
medication due to an adverse vent. 
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Conclusion: In this pilot study in hyperlipidemic patients with insulin resis- 
tance, 12 weeks of treatment with atorvastatin 10 mg QD was effective in control- 
ling hyperlipidemia but did not reduce the severity of insulin resistance. (Curr 
Ther Res Clin Exp. 2006;67:44-54) Copyright © 2006 Excerpta Medica, Inc. 
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INTRODUCTION 
The metabolic syndrome, also known as Reaven syndrome or insulin resistance 
syndrome, increases the risk for cardiovascular disease (CVD). 1-3 The metabol- 
ic syndrome is the consequence of genetic predisposition and lifestyle factors 
(eg, obesity-inducing dietary habits, physical inactivity). 1 Characteristics of the 
metabolic syndrome are abdominal obesity (body mass index [BMI], >30 kg/m 2, 
given that BMI and waist circumference >102 cm [men], >88 cm [women] are 
strongly correlated), dyslipidemia (triglyceride [TG] level, >150 mg/dL; high- 
density lipoprotein cholesterol [HDL-C] level, <40 mg/dL in men and <50 mg/dL 
in women), hypertension (systolic blood pressure [SBP], _>130 mm Hg; dia- 
stolic blood pressure [DBP], _>85 mm Hg; or receiving antihypertensive tr at- 
ment), elevated fasting plasma glucose (FPG) (>110 mg/dL), impaired glucose 
tolerance or diabetes mellitus (DM), microalbuminuria (30-300 mg/dL), and 
prothrombotic and proinflammatory states. 4 Insulin resistance plays a key 
role in the pathogenesis of the metabolic syndrome. 1 A number of studies 
have investigated the correlation between insulin resistance and the compo- 
nents of the metabolic syndrome, especially with DM, abdominal obesity, 
and/or hypertension. 5 Inparticular, the relationship between DM and the athero- 
sclerotic process has been examined in detail. 6-8 However, based on a MEDLINE 
search (key terms: hyperlipidemia and insulin resistance), data are limited re- 
garding the presence of insulin resistance in hyperlipidemic patients who have 
no other CVD risk factors that are components of the metabolic syndrome. 
In addition to their cholesterol-lowering effects, hydroxymethylglutaryl 
co-enzyme A reductase inhibitors ("statins") modify endothelial function, 
inflammatory esponse, and thrombus formation on atheromatous plaques. 9q2 
Insulin resistance increases the mitogenic activation of growth factors on 
the atheromatous plaques, and it might result in platelet aggregation, throm- 
bus formation, and endothelial dysfunction. 13 Statins have nonlipid pleiotropic 
effects, l°,n The results of several studies of the effects of statin treatment on 
hyperlipidemic patients with type 2 DM have been contradictory. 14-16 One 
study 14 found that statin treatment improved insulin action. But the other 
findings 15,16 were a lack of any effect on insulin resistance or a worsening 
of insulin action. The pleiotropic effects of statins, especially corrective 
effects on endothelial dysfunction, might decrease the severity of insulin 
resistance. 12
Our study aimed to investigate the effects of atorvastatin on insulin resis- 
tance in hyperlipidemic patients. 
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PATIENTS AND METHODS 
Study Population and Design 
This 12-week, prospective, nonrandomized, open-label study was conducted 
at the outpatient cardiology clinic at Ege University Medical School, Bornova- 
Izmir, Turkey. This was a convenience sample. Male and female hyperlipidemic 
patients aged _>18 years with insulin resistance (homeostasis model assessment 
[HOMA] index, 17 >2.718), plasma total cholesterol (TC) level >240 mg/dL, a TG 
level between 200 and 400 mg/dL, despite receiving the American Heart 
Association Step I diet 19 for at least 12 weeks before the study, and stable body 
weight for 8 weeks before the study were enrolled. 
Patients were excluded from the study if they were obese (BMI, >30 kg/m2), 
hypertensive (SBP/DBP, _>130/_>85 mm Hg, or receiving antihypertensive medi- 
cation), had impaired glucose tolerance (FPG level, _>110 mg/dL or plasma glu- 
cose >140 mg/dL on 2-hour 75-g oral glucose tolerance test), hepatic insuffi- 
ciency (serum aspartate aminotransferase or alanine aminotransferase activity, 
_>2-fold the upper limit of normal [x  ULN]), renal insufficiency (serum creati- 
nine level, _>2.0 mg/dL), serum creatine kinase activity >--3 x ULN, secondary 
pathologies leading to hyperlipidemia (eg, renal or thyroid dysfunction), and/or 
intensive alcohol consumption habits. Patients were also excluded if they were 
being treated with medications affecting insulin, glucose, or lipid metabolism. 
Patients with psychiatric abnormalities and women who were pregnant, could 
become pregnant, or were breastfeeding were also excluded. 
The study protocol was approved by the Turkish Society of Cardiology 
project and ethics board. All details of the study were explained to the pa- 
tients, and all patients provided their written consent before they entered 
the study. Patients were not allowed to receive any additional medications 
during the study. Patients were requested to continue following the American 
Heart Association Step I diet 19 throughout the study. 
Study Drug Administration 
Patients received atorvastatin 10 mg QD (after the evening meal) by mouth 
(table0 for 12 weeks. 
Efficacy and Tolerability Assessments 
The primary end point of the present study was the change from baseline 
(week 0) to study end (week 12) in the HOMA index. The secondary end points 
were changes from baseline to study end in serum levels of TC, HDL-C, low-density 
lipoprotein cholesterol (LDL-C), and TG; FPG; and fasting plasma insulin (FPI). 
Fasting blood samples were collected to determine lipid parameters before 
study drug administration on day 1 and at the end of the 12-week treatment 
period. Routine biochemistry and tolerability assessments were conducted at 
baseline and weeks 4 and 12. 
Serum levels of TC, HDL-C, and TG were assessed enzymatically using an 
autoanalyzer (Dax 48, Bayer Diagnostics, Toshiba, Japan). LDL-C level was cal- 
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culated using the Friedewald formula. 2° Serum levels of apolipoprotein 
(apo) A1 and apo B were assayed using an autoanalyzer (model 704, Hitachi, 
Tokyo, Japan) with turbidimetry (Boehringer Mannheim GmbH, Mannheim, 
Germany). FPI level was measured using an enzyme immunoassay method 
(Coat-A-Count Insulin, Diagnostic Products Corporation, Los Angeles, 
California). The presence of insulin resistance was assessed using the 
HOMA index 17 at baseline and 12 weeks. A HOMA index >2.7 was consid- 
ered to be insulin resistance. 18BMI was measured and waist/hip ratio was 
calculated in each patient before and after treatment. Sitting blood pressure 
and pulse rate were measured at baseline and 12 weeks. Blood pressure 
was measured in the same arm each time by the same person, using a 
standard cuff sphygmomanometer. The median of 3 measurements was 
used. 
The tolerability of atorvastatin was assessed using laboratory analysis 
and physical examination, including vital sign measurements, and documen- 
tation of the type, frequency, severity, duration, and relationship to treat- 
ment of any adverse events. Patients were directly asked about adverse 
events. 
Statistical Analysis 
Because of the small number of study patients, the Wilcoxon rank sum test was 
applied to assess the differences in values between baseline and after 12 weeks 
of atorvastatin treatment. P < 0.05 was considered significant. Statistical analyses 
were performed using SPSS version 10.0 (SPSS Inc., Chicago, Illinois). All values 
are expressed as mean (SD). 
RESULTS 
The study population comprised 15 white patients (9 women, 6 men; mean [SD] 
age, 52 [8] years). None of the patents had significant disease. 
Efficacy 
No significant changes between baseline and 12 weeks of atorvastatin treat- 
ment were found in BMI or waist/hip ratio (26.8 [2.7] vs 26.5 [2.3] kg/m 2 and 0.90 
[0.04] vs 0.90 [0.07], respectively). Atorvastatin significantly lowered fasting 
serum levels of LDL-C (173.2 [21.3] vs 110.8 [43.6] mg/dL), TC (270.9 [21.5] vs 
201.2 [46.7] mg/dL), and TG (269.5 [46.3] vs 205.5 [49.3] mg/dL) (all, P < 0.001). 
No statistically significant difference was found in HDL-C level (45.5 [6.6] vs 43.7 
[8.1] mg/dL) after treatment. Apo B level decreased significantly (147.6 [16.5] vs 
102.3 [19.7] mg/dL; P< 0.001), whereas apo A1 level did not change significantly 
(131.7 [38.2] vs 130.4 [15.7] mg/dL). No significant changes were found in FPG 
(85.3 [12.7] vs 84.8 [10.4] mg/dL) or FPI (13.5 [9.7] vs 13.9 [10.1] pU/mL). No sta- 
tistically significant difference in the HOMA index was observed at the end of 
treatment (3.1 [1.5] vs 3.2 [1.9]) (Table I). 
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Table I. Clinical characteristics before (baseline) and after 12 weeks of treatment 
with atorvastatin 10 mg/d in patients with hyperlipidemia nd insulin resis- 
tance (N = 15). Values are mean (SD). 
Characteristic Baseline 12 Weeks P 
BMI, kg/m 2 26.8 (2.7) 26.5 (2.3) 0.683 
WHR 0.90 (0.04) 0.90 (0.07) 1.000 
LDL-C, mg/dL 173.2 (21.3) 110.8 (43.6) <0.001 
HDL-C, mg/dL 45.5 (6.6) 43.7 (8.1) 0.495 
TC, mg/dL 270.9 (21.5) 201.2 (46.7) ¢0.001 
TG, mg/dL 269.5 (46.3) 205.5 (49.3) ¢0.001 
Apo A1, mg/dL 131.7 (38.2) 1 30.4 (15.7) 0.901 
Apo B, mg/dL 147.6 (16.5) 102.3 (19.7) ¢0.001 
FPG, mg/dL 85.3 (12.7) 84.8 (10.4) 0.897 
FPI, IJU/mL 13.5 (9.7) 13.9 (10.1) 0.903 
HOMA index* 3.1 (1.5) 3.2 (1.9) 0.898 
BMI = body mass index; WHR = waist/hip ratio; LDL-C = low-density lipoprotein cholesterol; HDL-C = 
high-density lipoprotein cholesterol; TC = total cholesterol; TG = triglycerides; apo = apolipoprotein; 
FPG = fasting plasma glucose; FPI = fasting plasma insulin; HOMA = homeostasis model assessment. 16 
*HOMA index >2.7 = insulin resistance. 17 
Tolerability 
No significant differences in SBP (124.1 [12.7] vs 128.3 [12.4] mm Hg), DBP 
(78.7 [9.4] vs 79.1 [10.1] mm Hg), or heart rate (75.0 [7.2] vs 75.9 [9.9] bpm) 
were found between baseline and posttreatment values. No significant changes 
were observed in serum alanine aminotransferase, aspartate aminotransferase, 
or creatine kinase activity in any of the patients (Table II). 
Atorvastatin was well tolerated. None of the patients required withdrawal of 
medication due to an adverse vent. Moderate dyspepsia was seen in 1 patient. 
DISCUSSION 
Insulin resistance syndrome has been associated with several complications 
related to CVD, some of which could be life threatening. 2° Important CVD risk 
factors (eg, DM, hypertension, hyperlipidemia) might result in endothelial dys- 
function, vascular inflammation, and prothrombotic events that might lead to 
atherosclerosis and its complications, uch as acute coronary syndromes, ud- 
den cardiac death, or congestive heart failure. Insulin resistance is at the cen- 
ter of these events. 1,13 The presence and the treatment of insulin resistance 
have been investigated intensively, especially in patients with type 2 DM. The 
Coronary Artery Risk Development inYoung Adults (CARDIA) study 23 examined 
insulin and lipids in black and white young adults. The investigators in the epi- 
demiologic CARDIA study 23 reported that plasma insulin levels were positively 
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Table II. Clinical and laboratory findings before (baseline) and after 12 weeks of 
treatment with atorvastatin 10 mg/d in patients with hyperlipidemia nd 
insulin resistance (N = 15). Values are mean (SD). 
Characteristic Baseline 12 Weeks P 
SBP, mm Hg 124.1 (12.7) 128.3 (12.4) 0.267 
DBP, mm Hg 78.7 (9.4) 79.1 (10.1) 0.821 
HR, bpm 75.0 (7.2) 75.9 (9.9) 0.798 
ALT, IU/dL 22.4 (9.5) 21.7 (6.1) 0.848 
AST, IU/dL 24.9 (15.2) 23.5 (9.9) 0.737 
CK, IU/dL 11 3.2 (59.4) 101.5 (42.7) 0.515 
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; ALl- = alanine amino- 
transferase; AST = aspartate aminotransferase; CK = creatine kinase. 
correlated with blood pressure and plasma levels of TG, TC, and LDL-C, and 
negatively correlated with plasma levels of HDL-C and apo A1 in both racial 
groups, a result independent of age, sex, and BMI. A number of methods (eg, 
oral glucose tolerance test, FPG, FPI, euglycemic clamp, glycosylated hemoglo- 
bin [HbAlc], HOMA index) have been used to determine insulin resistance. 17A8,21 
Although the euglycemic clamp is the most sensitive technique, its use is lim- 
ited because it is complex and time-consuming. 18 The HOMA index is being 
used with increasing frequency in clinical studies 17,18,25 and has been shown to 
be a reliable, rapid method of determining insulin resistance. We used the 
HOMA index to measure insulin resistance because its results have been shown 
to be reliable, rapid, and scientifically accepted. 18,21,23 
In the 1994 Scandinavian Simvastatin Survival Study (4S), 28 a distinct decrease 
in the total mortality rate was found in 4444 patients with stable coronary artery 
disease and elevated TC and LDL-C levels who were treated with simvastatin. 
This finding promoted statin use and the onset of secondary and primary pre- 
vention studies. 25-28 Statin therapy has been found to result in mild regression of 
fixed atherosclerotic lesions on angiography, and statins have also been shown 
to have pleiotropic nonlipid effects in and around the atherosclerotic lesions. 29 
Beneficial effects were found to be independent of cholesterol levels. 29 Statins 
have been associated with increased endothelial nitric oxide synthase l vels and 
improved endothelial function, 3° and diminished inflammatory activity. 26,27 Stat- 
ins also have been found to affect coagulation and thrombocytic functions 
(eg, by inhibiting thrombocytic aggregation and adhesion and by decreasing fi-
brinogen and plasminogen activator inhibitor 1 levels). 31 
Results from studies of the effects of statins on insulin resistance are conflict- 
ing. Various studies have found an increase, no change, or a decrease in insulin 
resistance. 24,30-37 Some studies 24,32,33,36 of statins have assessed efficacy in dia- 
betic, hyperlipidemic patients, and most have used lovastatin, simvastatin, 
and/or pravastatin. In a randomized, single-blind study in 195 patients with type 
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2 DM, Paolisso et a124 investigated the effects of statin therapy on insulin resis- 
tance using the HOMA index. Patients were randomly assigned to receive sim- 
vastatin 10 mg/d, atorvastatin 5 rag/d, or placebo for 8 weeks. Statin treatment 
was found to be effective in controlling dyslipidemia in these patients, and 
insulin resistance was decreased significantly (P < 0.05). In a double-blind, 
placebo-controlled, parallel-group study (atorvastatin 10 mg/d vs placebo) in 
40 hyperlipidemic patients with type 2 DM, Tanaka et a132 measured fasting lev- 
els of HbAlc and fructosamine as indices of glycemic ontrol. They reported 
that atorvastatin was well tolerated and associated with significantly decreased 
LDL-C, but no significant effects on glycemic ontrol were found. Our study was 
different from the study by Tanaka et a132 in that our study population was nor- 
moglycemic. The duration of treatment and the insulin resistance identification 
method in our study were similar to those of Paolisso et al, 24 and the atorva- 
statin dose used was similar to that of Tanaka et al. 32 Furthermore, like Tanaka 
et al, 32 we did not observe any effects on current insulin resistance with atorva- 
statin use. Similar conflicting results were also found in other statin studies. 33-36 
In a 9-week, randomized, ouble-blind, crossover study in 12 elderly patients 
with type 2 DM, Paolisso et a114 compared the effects of simvastatin 30 mg/d 
with those of placebo. Using the euglycemic lamp method to investigate 
insulin sensitivity, the investigators found that simvastatin was associated with 
improved lipid and glucose metabolism and decreased insulin resistance signifi- 
cantly. Sweany et a133 compared the lipid-altering effects and tolerability of sim- 
vastatin with those of gemfibrozil n 168 hyperlipidemic patients with type 2 DM 
in a 24-week, double-blind, randomized, multicenter t ial. Patients were ran- 
domly assigned to receive simvastatin 10 mg QD (titrated up to 40 mg/d to 
achieve an LDL-C level <3.4 mmol/L) or gemfibrozil 600 mg BID. They found 
no significant differences between baseline and posttreatment FPG or HbAlc lev- 
els between the 2 treatment groups. In a randomized, double-blind, placebo- 
controlled, crossover trial in 120 hyperlipidemic patients, Jula et a134 investigated 
the effects of simvastatin 20 mg/d alone or in combination with a modified iet 
on lipid parameters and FPG. They reported improvement in lipid parameters 
(all, P < 0.001) but an increase in insulin resistance (P-- 0.005) after 12 weeks of 
therapy. In a study in 18 patients with primary hyperlipidemia randomly 
assigned to receive simvastatin 20 mg/d or placebo for 8 weeks, Altunbas et a135 
investigated insulin sensitivity using the euglycemic clamp method. The inves- 
tigators found that simvastatin treatment was not associated with any effects 
on short-term insulin sensitivity. Similar contradictory results have been ob- 
served in pravastatin studies. In a 14-week, prospective, open-label study in 
23 patients with DM and hyperlipidemia who did not achieve the target lipid lev- 
els with low-dose (20 mg/d) pravastatin alone, Gardner et a136 studied the effects 
of the addition of niacin 1.5 g/d to a regimen containing pravastatin 20 mg/d 
on insulin sensitivity (FPG and fructosamine l vels). The investigators found 
no significant differences in insulin sensitivity when niacin was added to 
pravastatin treatment. In another study, Sheu et a137 treated hyperlipidemic 
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patients with pravastatin 10 to 20 mg/d for 12 weeks and reported significant 
improvement in the LDL-C level but no significant improvement or even wors- 
ening of hyperglycemia, insulin resistance, impairment of glucose tolerance, 
and hyperinsulinemia. 
Paolisso et a124 hypothesized that the positive effects of statins on insulin re- 
sistance might be associated with decreased plasma TG levels in patients 
with type 2 DM, noted that elevated TG levels were associated with impaired 
oxidative and nonoxidative insulin-mediated glucose metabolism, and noted 
that reducing TG levels might be inversely correlated with glucose metabolism. 
Although this hypothesis seems reasonable, improvement in insulin resistance 
was not found in other studies of statins 33-36 or in our study, in which TG levels 
were markedly reduced. 
Another possible hypothesis is that statins reduce mevalonate levels by 
inhibiting hydroxymethylglutaryl coenzyme A reductase activity. Mevalonate 
metabolites are effective in insulin and insulin-like growth factor I (IGF-I) signal- 
ing pathways. 38,39 The response to IGF-I and insulin in signaling pathways is re- 
duced when vascular smooth muscle cell cultures are exposed to lovastatin. 39
In 1 study, 39 human fibroblasts treated with the antihypercholesterolemic drug, 
lovastatin, displayed a diminished signaling response to epidermal growth fac- 
tor, insulin, and IGF-I. Supplementing the culture medium with mevalonic acid 
restored the signaling response. In addition, lovastatin has been found to in- 
hibit insulin receptor/IRS-1/P-I-3 complex formation. 4°All of these effects have 
been eliminated with mevalonate use .  39 
It has been hypothesized that phosphatidylinositol kinase 3 inhibitors 
have been associated with reduced insulin-mediated glucose transport. 41
Lovastatin has been associated with a reduction in phosphatidylinositol 
kinase 3 levels by reducing mevalonate l vels. 42 Theoretically, statins could 
reduce insulin-mediated glucose uptake by improving postreceptor insulin 
signaling, thereby reducing insulin sensitivity. When we consider this hy- 
pothesis, negative results would be expected from the studies of statins and 
insulin resistance because of reducing insulin-mediated glucose uptake. 
However, the results of most clinical s tud ies  32,33,35,36 of statins have been 
neutral, and some 14-24 have had positive results; insulin resistance was not 
reduced with atorvastatin treatment in our study. Similar s tud ies  14,24,33-37 
have had mean treatment periods of 4 to 24 weeks. The treatment period in 
our study was 12 weeks. Because the patients in our study had no CVD risk 
factors other than insulin resistance, we found it appropriate to administer 
atorvastatin at a dose of 10 mg/d. We noted that previous studies also used 
statins at recommended doses .  14,24,33-37 
In this study, treatment with atorvastatin 10 mg/d was not associated with 
any significant changes in insulin resistance. However, a possible positive or 
negative ffect of atorvastatin might have been missed due to the small sample 
size or the dose used. A larger study using a higher dose and a control group, 
together with a longer treatment period, are needed. 
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CONCLUSION 
This short-term pilot study in patients with hyperl ipidemia nd insulin resis- 
tance suggested that 12-week atorvastatin treatment was effective in controlling 
hyperl ipidemia but did not decrease the severity of insulin resistance. 
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